Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03193281 |
| KISS Study: Kinase Inhibition With Sprycel Start up(KISS) |
| unknown |
| Phase 2 |
| 91 |
| University of Auckland, New ZealandOTHER |
| 1 |
| Nov 29, 2023 |
| clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05329025 | A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03906669 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.(WinPro) | unknown | Phase 2 | 200 | St Vincent's HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06107114 | Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma(CZCNRHNSCC) | unknown | Phase 2 | 52 | Xuekui LiuOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06143735 | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | unknown | Phase 2 | 99 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05918198 | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Peking University People's HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142318 | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 66 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05812534 | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases(CBC) | unknown | Phase 2 | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT02624128 | Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck(V-CHANCE) | unknown | Phase 2 | 39 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05311709 | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities(SOLUCOM) | unknown | Phase 2 | 100 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125171 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | unknown | Phase 2 | 46 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT05234658 | Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery | unknown | Phase 2 | 21 | Andalusian Network for Design and Translation of Advanced TherapiesOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05490485 | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04467801 | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy(Ipat-Lung) | unknown | Phase 2 | 60 | Jun Zhang, MD, PhDOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05863325 | A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03088059 | Biomarker-based Study in R/M SCCHN(UPSTREAM) | unknown | Phase 2 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 3, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT03742193 | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy(PROACH) | unknown | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06111625 | Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06108726 | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | Phase 2 | 16 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06105658 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | unknown | Phase 2 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 1, 2023source: clinicaltrials